Trial Profile
Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2011 Results assessing the effects of treatment on health-related quality of life published in the European Journal of Cancer.
- 07 Jun 2011 Quality of life results (after 2 years) presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 20 Jan 2011 Results published in Lancet Oncology